STOCK TITAN

BIOA - BIOA STOCK NEWS

Welcome to our dedicated news page for BIOA (Ticker: BIOA), a resource for investors and traders seeking the latest updates and insights on BIOA.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BIOA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BIOA's position in the market.

Rhea-AI Summary
BioArctic AB (Nasdaq Stockholm: BIOA B) partner Eisai's Scientific Advisory Group (SAG) to discuss lecanemab's Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA) in Q1 2024. Eisai expects European Commission's decision in Q2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.51%
Tags
none
-
Rhea-AI Summary
BioArctic AB's (Nasdaq Stockholm: BIOA B) partner Eisai announced that Leqembi has been approved in China as a treatment for mild cognitive impairment and mild AD dementia due to Alzheimer's disease. Leqembi is the first approved treatment shown to reduce the rate of disease progression and slow cognitive and functional decline. The drug is based on the large global Phase 3 Clarity AD study, where it met its primary endpoint and all key secondary endpoints with statistically significant results. Eisai estimates that there are 17 million patients with MCI or mild dementia due to AD in China today, which is expected to increase with the aging of the population. BioArctic has a long-term collaboration with Eisai regarding the development and commercialization for Leqembi. Eisai is responsible for the clinical development, applications for market approval, and commercialization of the drug. BioArctic has no development costs for Leqembi in Alzheimer's disease and is entitled to payments in connection with certain regulatory approvals, and sales milestones as well as royalties on global sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
none
-
Rhea-AI Summary
BioArctic AB's (Nasdaq Stockholm: BIOA B) partner Eisai announced the launch of LEQEMBI in Japan on December 20, following its inclusion in the price listing on the Japan National Health Insurance drug price list. The product obtained approval for the indication of slowing progression of mild cognitive impairment and mild dementia due to Alzheimer's disease in Japan on September 25, 2023. LEQEMBI selectively binds to soluble and insoluble amyloid-beta aggregates, reducing Aβ protofibrils and plaques in the brain. The launch in Japan makes it the second country to have the product on the market, following the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.24%
Tags
none
Rhea-AI Summary
BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) invention lecanemab (LEQEMBI®), partnered with Eisai, was awarded the Best New Drug and the award for the Clinical Advance of the Year at the Scrip Awards 2023. The awards celebrate the best innovations and achievements of the international biopharma industry. Lecanemab is recognized for its excellence in pharmaceutical development, being the first and only treatment approved in Japan and the United States shown to reduce the rate of disease progression and to slow cognitive and functional decline in Alzheimer's disease patients. The success of the Phase 3 Clarity AD study of lecanemab led to the award for Clinical Advance of the Year. BioArctic and Eisai are preparing for a joint commercialization of lecanemab in the Nordic region.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
none
-
Rhea-AI Summary
BioArctic AB's partner Eisai reported sales of 0.4 billion yen for LEQEMBI in the third quarter of 2023, resulting in a royalty of SEK 2.5 million for BioArctic. BioArctic has the right to commercialize lecanemab in the Nordic region and is preparing for joint commercialization with Eisai in the region.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.93%
Tags
earnings
-
Rhea-AI Summary
BioArctic's partner Eisai presented new data on the investigational subcutaneous formulation of LEQEMBI at the Clinical Trials on Alzheimer's Disease conference. The data showed that the subcutaneous formulation clears 14% more amyloid plaques and has higher pharmacokinetics compared to intravenous infusion. The company aims to submit a Biologics License Application with the FDA by March 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.06%
Tags
clinical trial
Rhea-AI Summary
BioArctic's lecanemab selected as one of the Best Inventions of 2023 by TIME for its treatment of Alzheimer's disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
none
-
Rhea-AI Summary
BioArctic AB's partner Eisai will present new data on the Alzheimer's disease treatment LEQEMBI® at the Clinical Trials on Alzheimer's Disease conference. BioArctic will also give an oral presentation on binding profiles of lecanemab and donanemab to different amyloid-beta species.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.31%
Tags
clinical trial
-
Rhea-AI Summary
BioArctic's partner Eisai receives approval for LEQEMBI in Japan as a treatment for Alzheimer's disease, entitling BioArctic to EUR 17 M milestone payment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
none
Rhea-AI Summary
BioArctic AB (publ) granted new drug substance patent for antibody BAN0805 as potential treatment for Parkinson's disease
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.68%
Tags
none
BIOA

Nasdaq:BIOA

BIOA Rankings

BIOA Stock Data